Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : World's First Use of Environmentally Friendly Biomass-based Plastic for Blister Packages, the Primary Packaging for Drugs

10/11/2021 | 02:12am EST

TOKYO, October 11, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") begin using biomass-based plastics made from plant-derived materials in blister packages as the primary packaging for pharmaceutical products. This is the world's first use of biomass plastic for blister packages for drugs.

General plastic blister package

The blister package is made of biomass-based plastic, polyethylene derived from sugarcane, as 50% of its raw material. It is an environmentally friendly packaging that agree with the concept of "carbon neutrality," which is the idea of balancing greenhouse gas emissions and absorption.

Blister packages as tablet packaging containers are required to have high tablet protection and usability. For example, strength that can withstand impact and sealability that will keep outside air from entering, while maintaining enough softness so that the tablets can be easily taken out. The visibility of the packaged tablets and the ease in which it can be separated is also required. Astellas, by fully using its packaging technology cultivated over many years, has actualized the production of the biomass-based plastic sheets that can be mass-produced while achieving tablet protection function and usability.

In FY2021, Astellas will start using the biomass-based plastic blister package for the "Irribow® Tablet 5µg" (generic name: ramosetron hydrochloride, indication: diarrhea-predominant irritable bowel syndrome) in Japan. In the future, Astellas will continue to switch from the conventional petroleum-derived plastic blister package to the biomass-based plastic blister package for other products as well, and it will also seek new packaging materials that are superior in terms of sustainability.

Astellas has set "Deepen our Engagement in Sustainability" as one of its strategic goals in its Corporate Strategic Plan 2021*1. The adoption of biomass-based plastics in blister packages is one of the efforts toward this end. Astellas also believe that this will contribute to Goal 13 of the SDGs (Sustainable Development Goals), "Take urgent action to combat climate change and its impacts". Astellas continues to further promote sustainability activities and expand information disclosure under its basic policy, which is to improve the sustainability of both the global society and Astellas while keeping ESG [environmental (E), social (S), governance (G)] in mind*2.

*1: Astellas Corporate website "Corporate Strategic Plan 2021". Available at:
https://www.astellas.com/en/about/csp2021

*2: Astellas Corporate website "Sustainability Approach". Available at:
https://www.astellas.com/en/sustainability/sustainability-approach

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 11 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 October 2021 06:11:03 UTC.


ę Publicnow 2021
All news about ASTELLAS PHARMA INC.
03:32aASTELLAS PHARMA : Corporate Governance Report
PU
02:32aASTELLAS PHARMA : Applied for Selection of “Prime Market”segment of the Tokyo ..
PU
02:12aASTELLAS PHARMA : Applied for Selection of “Prime Market” segment of the Tokyo..
PU
12/05ASTELLAS PHARMA : Corporate Covernance Report
PU
12/02Astellas to Present Research on FLT3 Mutation, Positive Acute Myeloid Leukemia from Dia..
AQ
12/02Japanese shares end lower on Omicron worries, Fed's hawkish tilt
RE
12/01Japanese shares fall on Omicron, Fed worries
RE
12/01ASTELLAS PHARMA : to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia &nd..
PU
11/30ASTELLAS PHARMA : Patient centricity at Astellas—all about action
PU
11/30WE PUBLISHED A STORY : “Patient centricity at Astellas—all about action.&rdquo..
PU
More news
Financials
Sales 2022 1 327 B 11 696 M 11 696 M
Net income 2022 183 B 1 613 M 1 613 M
Net cash 2022 380 B 3 348 M 3 348 M
P/E ratio 2022 17,8x
Yield 2022 2,83%
Capitalization 3 270 B 28 823 M 28 818 M
EV / Sales 2022 2,18x
EV / Sales 2023 1,91x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 765,00 JPY
Average target price 2 458,33 JPY
Spread / Average Target 39,3%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.10.73%29 201
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641